RNAi Therapeutics and Technology Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 5.28 Bn by the year 2031 at a 16.0% CAGR during the forecast period for 2024-2031.
RNA interference (RNAi) therapeutics and technology represent a cutting-edge approach to disease treatment, utilizing the cell's natural regulatory mechanism to silence specific genes implicated in various disorders. At the core of RNAi technology lie small interfering RNA (siRNA) and microRNA (miRNA) molecules, which target and neutralize disease-causing genes with remarkable precision when introduced into the body. Through this mechanism, RNAi therapeutics offer a tailored and potent means of addressing a broad spectrum of medical conditions.
The applications of RNAi therapeutics span various diseases, ranging from genetic disorders and oncological malignancies to viral infections and neurodegenerative conditions. RNAi therapies hold promise in preventing diseases at their molecular roots by selectively silencing target genes. Additionally, RNAi technology has demonstrated efficacy in addressing cardiovascular diseases, kidney ailments, respiratory disorders, and various infectious diseases, marking a transformative shift in the landscape of medical intervention.
The increasing investments in RNAi therapy development are driving the RNAi therapeutics market forward. Driven by the acknowledgement of RNAi technology's potency in precision medicine and its expansive therapeutic potential, biotech firms and pharmaceutical companies are eagerly engaged in research and development activities, injecting substantial funds into advancing RNAi-based treatments.
The RNAi therapeutics and technology market is segmented based on type, Delivery, route of administration and end-user. By Type, the segmentation comprises Small Interfering RNA (siRNA), MicroRNA (miRNA). As per the Route of Administration, the market includes Intravenous (IV) and Subcutaneous. According to the Delivery, the market is segmented into Lipid Nanoparticles (LNPs), Conjugates, Others.
The increasing preference for siRNA (small interfering RNA) in drug development stems from its exceptional specificity in targeting disease-causing genes, potent gene silencing activity, and advancements in delivery technologies, which collectively enhance therapeutic efficacy. SiRNAs' ability to precisely silence single genes minimizes off-target effects, making them attractive for various diseases. Moreover, the rise in research collaborations and partnerships has accelerated siRNA-based therapy development, aided by successful clinical outcomes and regulatory approvals. This collaborative momentum, coupled with ongoing advancements in the field, solidifies siRNA's position as the leading segment in the RNAi market for drug development, promising novel and effective treatments for diverse medical conditions.
North America, particularly the United States, leads the RNAi therapeutics market due to its robust biotechnology sector, encompassing top-notch universities and research institutions that drive innovation in RNAi technology. Supported by favorable regulatory agencies like the FDA, the region fosters the approval and commercialization of RNAi-based therapies. High healthcare expenditure levels and well-established healthcare systems further bolster the adoption of innovative treatments. Additionally, key players and collaborative efforts among biopharmaceutical companies and academic institutions actively propel the development and commercialization of RNAi-based treatments, solidifying North America's dominance in the global RNAi therapeutics market.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 1.6 Bn |
| Revenue Forecast In 2031 | USD 5.28 Bn |
| Growth Rate CAGR | CAGR of 16.0 % from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type, By Delivery, By Route of Administration, |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
| Competitive Landscape | Alnylam, Novartis, Novo Nordisk, Regulus therapeutics, miRagen therapeutics, Roche, Santaris, Sanofi Genzyme, AstraZeneca, Viridian, Mirna Therapeutics, Arbutus Biopharma, OliX Pharmaceuticals, Inc, and Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
RNAi Therapeutics and Technology Market by Type -
RNAi Therapeutics and Technology Market by Route of Administration -
RNAi Therapeutics and Technology Market by Delivery-
RNAi Therapeutics and Technology Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.